UY31510A1 - Vacunacontra la malaria, especifica para el parasito plasmodium falciparum - Google Patents
Vacunacontra la malaria, especifica para el parasito plasmodium falciparumInfo
- Publication number
- UY31510A1 UY31510A1 UY31510A UY31510A UY31510A1 UY 31510 A1 UY31510 A1 UY 31510A1 UY 31510 A UY31510 A UY 31510A UY 31510 A UY31510 A UY 31510A UY 31510 A1 UY31510 A1 UY 31510A1
- Authority
- UY
- Uruguay
- Prior art keywords
- malaria
- vacunacontra
- specific
- viral vector
- plasmodium falciparum
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title abstract 3
- 241000223960 Plasmodium falciparum Species 0.000 title abstract 2
- 244000045947 parasite Species 0.000 title 1
- 239000013603 viral vector Substances 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se divulga un vector adenovírico de simio deficiente de replicacion C7 que codifica una proteína que comprende la proteína CS de P. falciparum o un fragmento de la misma. Se divulgan procedimientos de preparacion de dicho vector vírico y el uso del vector vírico en el tratamiento/prevencion de infeccion por malaria. Se describe composiciones, vacunas y kits que comprenden dicho vector.Se describe el uso de un vector vírico C7 sintético. El vector vírico C7 puede coadministrarse o coformularse con un antígeno de la malaria tal como RTS, S y opcionalmente en presencia de un coadyuvante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99280207P | 2007-12-06 | 2007-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31510A1 true UY31510A1 (es) | 2009-08-03 |
Family
ID=40591828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY31510A UY31510A1 (es) | 2007-12-06 | 2008-12-04 | Vacunacontra la malaria, especifica para el parasito plasmodium falciparum |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2227550A2 (es) |
| JP (1) | JP2011505796A (es) |
| KR (1) | KR20100108544A (es) |
| CN (1) | CN101939438A (es) |
| AR (1) | AR069568A1 (es) |
| AU (1) | AU2008333208A1 (es) |
| BR (1) | BRPI0819889A2 (es) |
| CA (1) | CA2707245A1 (es) |
| CL (1) | CL2008003614A1 (es) |
| CO (1) | CO6300795A2 (es) |
| CR (1) | CR11537A (es) |
| DO (1) | DOP2010000164A (es) |
| IL (1) | IL205953A0 (es) |
| MA (1) | MA32003B1 (es) |
| MX (1) | MX2010006207A (es) |
| PE (1) | PE20091106A1 (es) |
| TW (1) | TW200938633A (es) |
| UY (1) | UY31510A1 (es) |
| WO (1) | WO2009071613A2 (es) |
| ZA (1) | ZA201003851B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815872D0 (en) * | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| EP3632463A1 (en) * | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| RU2356577C9 (ru) * | 2002-10-23 | 2009-08-10 | Глаксосмитклайн Байолоджикалс С.А. | Способы вакцинации против малярии |
| AU2003298361B2 (en) * | 2002-12-17 | 2009-05-14 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| WO2005063805A1 (en) * | 2003-12-23 | 2005-07-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection |
| DE602005017743D1 (de) * | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| RS52187B (sr) * | 2004-10-14 | 2012-10-31 | Crucell Holland B.V. | Vakcine za indukciju i stimulaciju imunskog odgovora za malariju |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| WO2007110409A1 (en) * | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| CA2657279A1 (en) * | 2006-07-18 | 2008-01-24 | Glaxosmithkline Biologicals S.A. | Vaccines for malaria |
| LT2137210T (lt) * | 2007-03-02 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Naujas būdas ir kompozicijos |
| GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
-
2008
- 2008-12-04 TW TW097147198A patent/TW200938633A/zh unknown
- 2008-12-04 JP JP2010536451A patent/JP2011505796A/ja active Pending
- 2008-12-04 AR ARP080105281A patent/AR069568A1/es not_active Application Discontinuation
- 2008-12-04 UY UY31510A patent/UY31510A1/es unknown
- 2008-12-04 WO PCT/EP2008/066762 patent/WO2009071613A2/en not_active Ceased
- 2008-12-04 AU AU2008333208A patent/AU2008333208A1/en not_active Abandoned
- 2008-12-04 KR KR1020107014859A patent/KR20100108544A/ko not_active Withdrawn
- 2008-12-04 CA CA2707245A patent/CA2707245A1/en not_active Abandoned
- 2008-12-04 PE PE2008002018A patent/PE20091106A1/es not_active Application Discontinuation
- 2008-12-04 CN CN2008801267101A patent/CN101939438A/zh active Pending
- 2008-12-04 EP EP08857977A patent/EP2227550A2/en not_active Withdrawn
- 2008-12-04 CL CL2008003614A patent/CL2008003614A1/es unknown
- 2008-12-04 MX MX2010006207A patent/MX2010006207A/es not_active Application Discontinuation
- 2008-12-04 BR BRPI0819889-6A patent/BRPI0819889A2/pt not_active IP Right Cessation
-
2010
- 2010-05-25 IL IL205953A patent/IL205953A0/en unknown
- 2010-05-28 ZA ZA2010/03851A patent/ZA201003851B/en unknown
- 2010-06-02 DO DO2010000164A patent/DOP2010000164A/es unknown
- 2010-06-10 CO CO10070274A patent/CO6300795A2/es not_active Application Discontinuation
- 2010-06-29 CR CR11537A patent/CR11537A/es not_active Application Discontinuation
- 2010-07-05 MA MA32991A patent/MA32003B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009071613A3 (en) | 2009-08-13 |
| MX2010006207A (es) | 2010-10-04 |
| KR20100108544A (ko) | 2010-10-07 |
| CO6300795A2 (es) | 2011-07-21 |
| WO2009071613A2 (en) | 2009-06-11 |
| CR11537A (es) | 2010-08-18 |
| IL205953A0 (en) | 2010-11-30 |
| PE20091106A1 (es) | 2009-08-24 |
| BRPI0819889A2 (pt) | 2015-06-16 |
| CN101939438A (zh) | 2011-01-05 |
| AU2008333208A1 (en) | 2009-06-11 |
| AR069568A1 (es) | 2010-02-03 |
| ZA201003851B (en) | 2012-11-28 |
| DOP2010000164A (es) | 2010-07-31 |
| MA32003B1 (fr) | 2011-01-03 |
| CL2008003614A1 (es) | 2010-01-15 |
| JP2011505796A (ja) | 2011-03-03 |
| TW200938633A (en) | 2009-09-16 |
| EP2227550A2 (en) | 2010-09-15 |
| CA2707245A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022003702A2 (es) | Vacunas para vhb y métodos de tratamiento de vhb | |
| WO2007120673A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| BR112018004242A2 (pt) | composições de vacina que possuem estabilidade e imunogenicidade aumentadas | |
| CY1117673T1 (el) | Ανασυνδυασμενα αντιγονα rsv | |
| WO2017191258A8 (en) | INFLUENZA MRNA VACCINES | |
| MX375202B (es) | Composiciones adyuvantes novedosas. | |
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| WO2009072767A3 (en) | A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant | |
| CL2011001993A1 (es) | Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto. | |
| UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
| AR093712A1 (es) | Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento | |
| AR102547A1 (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso | |
| CR11307A (es) | Vacunas | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| MX2016001695A (es) | Composiciones inmunogenas de combinacion. | |
| PH12014501795B1 (en) | Rotavirus subunit vaccines and methods of making and use thereof | |
| UY31510A1 (es) | Vacunacontra la malaria, especifica para el parasito plasmodium falciparum | |
| GB201112587D0 (en) | Vaccine | |
| EA201200538A1 (ru) | Арабиногалактан для повышения приобретенного иммунного ответа | |
| WO2007120603A3 (en) | Immunogenic bcr-abl peptides and methods of use thereof | |
| TN2010000338A1 (en) | Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant | |
| MX2021001641A (es) | Identificacion de proteinas inmunogenicas para el control de ectoparasitos. |